Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model

• Julia Ludwig,
• Stephen W. Scally,
• Giulia Costa,
• Sandro Hoffmann,
• Rajagopal Murugan,
• Jana Lossin,
• Katherine Prieto,
• Anna Obraztsova,
• Nina Lobeto,
• Blandine Franke-Fayard,
• Chris J. Janse,
• Celia Lebas,
• Nicolas Collin,
• Spela Binter,
• Paul Kellam,
• Elena A. Levashina,
• Hedda Wardemann,
• Jean-Philippe Julien

Affiliations

Julia Ludwig

B Cell Immunology, German Cancer Research Center (DKFZ)

Stephen W. Scally

Program in Molecular Medicine, The Hospital for Sick Children Research Institute

Giulia Costa

Vector Biology Unit, Max Planck Institute for Infection Biology

Sandro Hoffmann

B Cell Immunology, German Cancer Research Center (DKFZ)

Rajagopal Murugan

B Cell Immunology, German Cancer Research Center (DKFZ)

Jana Lossin

B Cell Immunology, German Cancer Research Center (DKFZ)

Katherine Prieto

Program in Molecular Medicine, The Hospital for Sick Children Research Institute

Anna Obraztsova

B Cell Immunology, German Cancer Research Center (DKFZ)

Nina Lobeto

B Cell Immunology, German Cancer Research Center (DKFZ)

Blandine Franke-Fayard

Malaria Research Group, Department of Parasitology, Leiden University Medical Center

Chris J. Janse

Malaria Research Group, Department of Parasitology, Leiden University Medical Center

Celia Lebas

Vaccine Formulation Institute

Nicolas Collin

Vaccine Formulation Institute

Spela Binter

Kymab a Sanofi Company, Babraham Research Campus

Paul Kellam

Kymab a Sanofi Company, Babraham Research Campus

Elena A. Levashina

Vector Biology Unit, Max Planck Institute for Infection Biology

Hedda Wardemann

B Cell Immunology, German Cancer Research Center (DKFZ)

Jean-Philippe Julien

Program in Molecular Medicine, The Hospital for Sick Children Research Institute